-
Get the latest information and research on osteoporosis.
-
Find treatment, guidance and advice on living with osteoporosis.
-
Share your experience and get involved. Joining the conversation is the first step to ending osteoporosis and broken bones.
Following is a statement by the National Osteoporosis Foundation on the U.S. Food and Drug Administration’s clearance for Optasia Medical’s SpineAnalyzer™
WASHINGTON, DC (February 22, 2011) — Osteoporosis is a serious, widespread and growing public health threat, according to the National Osteoporosis Foundation (NOF). When the disease is undiagnosed or untreated, it is marked by broken bones (fractures) which cause pain, disability and in some cases, reduced lifespan.
On February 4, 2011, the Optasia Medical SpineAnalyzer was cleared by the FDA. SpineAnalyzer is a tool that helps healthcare providers to identify broken bones in the spine. Patients with spinal fractures can then be treated for osteoporosis which reduces the risk for future fractures.
NOF welcomes any new FDA approved diagnostic options, such as SpineanalyzerTM, that will help patients address this prevalent disease. NOF estimates 10 million Americans have osteoporosis and another 34 million are at risk for the disease.
About the National Osteoporosis Foundation
Established in 1984, the National Osteoporosis Foundation, a leading community-focused health organization, is dedicated to the prevention of osteoporosis and broken bones, the promotion of strong bones for life and the reduction of human suffering through programs of awareness, education, advocacy and research. For more information on the National Osteoporosis Foundation, visit www.nof.org.
The latest
Last week, a Food and Drug Administration (FDA) Panel voted that the risks of calcitonin salmon outweigh the benefits for the treatment of postmenopausal osteoporosis. The panel joined health authorities around the world in reviewing the drug’s safety after two recent studies showed slightly higher rates of cancer among patients taking calcitonin. The panel voted against continued use of the drug by a narrow majority, pointing out that it has not been found very effective in preventing bone fractures.
In today's Washington Post article "Calcium and Vitamin D findings show that caring for your bones can be compilicated," NOF's senior clinical director, Dr. Felicia Cosman helps clear up some of the confusion around the recent and conflicting research on calcium and vitamin D. She says: "It’s confusing, even for doctors. But there’s a common thread: None of the heart or kidney risks were associated with calcium from food."
CIRCA, the leading international buyer of fine jewelry, diamonds and watches, announced a new partnership with NOF at a Generations of Strength luncheon at the Friars Club in New York City on February 26. To kick-off the partnership, CIRCA’s Acting CEO Mary L. Forté presented NOF Executive Director and CEO Amy Porter with a check for $25,000, to support NOF’s mission.
Explore by tag
